Pfizer Inc. (NYSE:PFE) Holdings Decreased by First PREMIER Bank

First PREMIER Bank reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,557 shares of the biopharmaceutical company’s stock after selling 560 shares during the quarter. First PREMIER Bank’s holdings in Pfizer were worth $801,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC grew its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the fourth quarter worth about $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Trading Up 0.4%

NYSE:PFE opened at $23.97 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock’s 50-day moving average is $23.26 and its two-hundred day moving average is $24.90. The stock has a market cap of $136.27 billion, a PE ratio of 17.37, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.82 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.18%. Pfizer’s payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.